🚀 VC round data is live in beta, check it out!
Teva Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Teva Pharmaceuticals and similar public comparables like BeOne Medicines, Sandoz, Otsuka Holdings, Daiichi Sankyo and more.
Teva Pharmaceuticals Overview
About Teva Pharmaceuticals
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Founded
1944
HQ
Employees
34.0K
Website
Sectors
Financials (LTM)
EV
$50B
Teva Pharmaceuticals Financials
Teva Pharmaceuticals reported last 12-month revenue of $17B and EBITDA of $5B.
In the same LTM period, Teva Pharmaceuticals generated $9B in gross profit, $5B in EBITDA, and $3B in net income.
Revenue (LTM)
Teva Pharmaceuticals P&L
In the most recent fiscal year, Teva Pharmaceuticals reported revenue of $17B and EBITDA of $5B.
Teva Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $17B | XXX | $17B | XXX | XXX | XXX |
| Gross Profit | $9B | XXX | $9B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $5B | XXX | $5B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | — | — | $13B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Teva Pharmaceuticals Stock Performance
Teva Pharmaceuticals has current market cap of $36B, and enterprise value of $50B.
Market Cap Evolution
Teva Pharmaceuticals' stock price is $31.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50B | $36B | -0.4% | XXX | XXX | XXX | $2.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTeva Pharmaceuticals Valuation Multiples
Teva Pharmaceuticals trades at 2.9x EV/Revenue multiple, and 9.4x EV/EBITDA.
EV / Revenue (LTM)
Teva Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Teva Pharmaceuticals has market cap of $36B and EV of $50B.
Equity research analysts estimate Teva Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Teva Pharmaceuticals has a P/E ratio of 10.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36B | XXX | $36B | XXX | XXX | XXX |
| EV (current) | $50B | XXX | $50B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 10.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 5.6x | XXX | XXX | XXX |
| P/E | 10.7x | XXX | 10.7x | XXX | XXX | XXX |
| EV/FCF | 20.2x | XXX | 20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Teva Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Teva Pharmaceuticals Margins & Growth Rates
Teva Pharmaceuticals' revenue in the last 12 month grew by 1%.
Teva Pharmaceuticals' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Teva Pharmaceuticals' rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Teva Pharmaceuticals' rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Teva Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Teva Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Teva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BeOne Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Sandoz | XXX | XXX | XXX | XXX | XXX | XXX |
| Otsuka Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Daiichi Sankyo | XXX | XXX | XXX | XXX | XXX | XXX |
| Alnylam Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Teva Pharmaceuticals M&A Activity
Teva Pharmaceuticals acquired XXX companies to date.
Last acquisition by Teva Pharmaceuticals was on XXXXXXXX, XXXXX. Teva Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Teva Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTeva Pharmaceuticals Investment Activity
Teva Pharmaceuticals invested in XXX companies to date.
Teva Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Teva Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Teva Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Teva Pharmaceuticals
| When was Teva Pharmaceuticals founded? | Teva Pharmaceuticals was founded in 1944. |
| Where is Teva Pharmaceuticals headquartered? | Teva Pharmaceuticals is headquartered in Israel. |
| How many employees does Teva Pharmaceuticals have? | As of today, Teva Pharmaceuticals has over 34K employees. |
| Who is the CEO of Teva Pharmaceuticals? | Teva Pharmaceuticals' CEO is Richard D. Francis. |
| Is Teva Pharmaceuticals publicly listed? | Yes, Teva Pharmaceuticals is a public company listed on NYSE. |
| What is the stock symbol of Teva Pharmaceuticals? | Teva Pharmaceuticals trades under TEVA ticker. |
| When did Teva Pharmaceuticals go public? | Teva Pharmaceuticals went public in 1982. |
| Who are competitors of Teva Pharmaceuticals? | Teva Pharmaceuticals main competitors are BeOne Medicines, Sandoz, Otsuka Holdings, Daiichi Sankyo. |
| What is the current market cap of Teva Pharmaceuticals? | Teva Pharmaceuticals' current market cap is $36B. |
| What is the current revenue of Teva Pharmaceuticals? | Teva Pharmaceuticals' last 12 months revenue is $17B. |
| What is the current revenue growth of Teva Pharmaceuticals? | Teva Pharmaceuticals revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Teva Pharmaceuticals? | Current revenue multiple of Teva Pharmaceuticals is 2.9x. |
| Is Teva Pharmaceuticals profitable? | Yes, Teva Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Teva Pharmaceuticals? | Teva Pharmaceuticals' last 12 months EBITDA is $5B. |
| What is Teva Pharmaceuticals' EBITDA margin? | Teva Pharmaceuticals' last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Teva Pharmaceuticals? | Current EBITDA multiple of Teva Pharmaceuticals is 9.4x. |
| What is the current FCF of Teva Pharmaceuticals? | Teva Pharmaceuticals' last 12 months FCF is $2B. |
| What is Teva Pharmaceuticals' FCF margin? | Teva Pharmaceuticals' last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Teva Pharmaceuticals? | Current FCF multiple of Teva Pharmaceuticals is 20.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.